Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Fig. 2

MEDI9197 is retained locally after injection. a-c Radiolabelled MEDI9197 distribution in male SD rats after SC injection. a, MEDI9197 distribution was measured in tissues by quantitative whole-body autoradiography 1 day and 28 days post-dose. Images of one rat serial transverse section (representative of two rats/time point). b and c Quantification of radiolabeled MEDI9197 at the injection site, plasma, and whole blood 4 to 672 h post-dose (mean, n = 2). d Rat serum TNFα levels following a single SC injection of 0.1, 0.3, and 1 mg/kg MEDI9197 or 0.3 mg/kg Resiquimod. The values at the 0 h time point are an average of 30 rats (1 serum sample per rat). The values shown at all other time points are an average of 5 rats (1 serum sample per rat). e MALDI-MSI images showing MEDI9197 and Heme distribution in B16-F10 AP3 tumors after a single 20 μg IT dose. Data are representative of 9 mice and 2 independent experiments. f Drug levels measured by HPLC-UV in B16-OVA tumors, implanted SC in C57BL/6-albino mice. After approximately 15 days, 50 μg MEDI9197 was injected IT, and tumors were collected immediately post-dose, 6 h, 3 days, and 14 days post-dose (5 mice/time point, 2 independent experiments). Tumor lysate drug levels are expressed as % of initial dose

Back to article page